Latest news with #RESTEM
Yahoo
06-06-2025
- Health
- Yahoo
RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress
MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design of its Phase 2/3 IIMPACT (Idiopathic Inflammatory Myopathy Phase 2/3 Adaptive Clinical Trial) trial of Restem-L, the Company's umbilical-lining modified progenitor cells (UMPC) program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). The oral presentation will be delivered at the European Alliance of Associations for Rheumatology's (EULAR) 2025 Congress, to take place June 11-14 in Barcelona, Spain. Details of the oral presentation are as follows: Abstract Title: Rationale and Study Design for a Phase 2/3, Double-blinded, Randomized, Dose-repeating, Cross-over Study to Assess Safety and Efficacy of Allogeneic Umbilical Cord Lining Stem Cells on Disease Severity and Steroid Tapering in Participants with Idiopathic Inflammatory Myopathy Abstract Number: OP0318 Session Title: Clinical Abstract Sessions: Novelties and innovative therapeutic strategies in inflammatory myopathies Session Date and Time: Friday, June 13, 2025, 10:30 AM CEST About Idiopathic Inflammatory Myopathy (IIM) Idiopathic inflammatory myopathies (IIM) are a group of conditions characterized by inflammation of muscles (myositis) and other body systems. Polymyositis and dermatomyositis are subtypes of IIM. Polymyositis causes inflammation and weakness of the skeletal muscles responsible for movement. Dermatomyositis is a form of polymyositis that is associated with skin rash, in addition to muscle inflammation. Both disorders can significantly compromise the quality of life and are very challenging to treat. Currently, the only treatment for these disorders is immunosuppressive drugs, which can be associated with significant toxicity and other side effects. About RESTEM RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products, robust clinical development expertise, and cutting-edge-manufacturing capabilities, we are advancing two potentially groundbreaking programs, Restem-L, our umbilical-lining modified progenitor cells (UMPC) program for autoimmune diseases; and our activated natural killer cell (aNK) therapeutics targeting senescence and age-associated disorders. Our therapies are uniquely positioned to redefine the standard of care for patients with limited options, by suggesting an immune system remodeling—rather than mere symptom suppression—offering a potential path to true disease resolution. RESTEM is headquartered in Miami, Florida. For more information, please visit and follow us on X and LinkedIn. Investor Contact Daniel Ferry LifeSci Advisors +1.617.430.7576 daniel@ Media Contact Nelson CabautanRestem Group, Inc. +1.800.490.0924 ncabatuan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-06-2025
- Business
- Yahoo
RESTEM to Present at the 2025 BIO International Convention
MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that Andres Isaias, its Chief Executive Officer, will present at the upcoming 2025 BIO International Convention taking place in Boston, MA from June 16 – 19, 2025. BIO International Convention Format: Corporate presentation and one-on-one meetings Presentation Date and Time: June 18, 2025, at 1:45 PM in Room 153A Location: Boston Convention & Exhibition Center, Boston, MA To register for the conference and schedule a one-on-one meeting with RESTEM's management, please visit About RESTEM RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products, robust clinical development expertise, and cutting-edge-manufacturing capabilities, we advance two potentially groundbreaking programs, Restem-L, our umbilical cord lining stem cells (ULSCs) program for auto-immune diseases and our natural killer cell (NK) therapeutics targeting senescence and age-associated disorders. Our therapies are intended to treat a broad range of disabling diseases and are designed to improve patient outcomes, as well as overall health and wellness. RESTEM is headquartered in Miami, Florida. For more information, please visit and follow us on X and LinkedIn. Investor Contact Daniel Ferry LifeSci Advisors +1.617.430.7576 daniel@ Media Contact Nelson CabautanRestem Group, Inc. +1.800.490.0924 ncabatuan@ in to access your portfolio
Associated Press
02-04-2025
- Business
- Associated Press
RESTEM to Participate in Jones Las Vegas Technology and Innovation Conference
NEWMEDIAWIRE) - RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its participation in the Jones Las Vegas Technology and Innovation Conference, to be held April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada. Andres Isaias, Chief Executive Officer of RESTEM, will be presenting a corporate overview of the Company on Wednesday, April 9, 2025, at 11:00 a.m. PT, in a virtual format. A live webcast of the presentation can be accessed here. A replay of the event will be available on the 'Corporate Presentation ' section of the RESTEM website after the conclusion of the event and will be archived on the RESTEM website at The Jones Conference is recognized for bringing together a select group of innovative companies and institutional investors for a two-day event. The event will be focused on one-on-one (1x1) meetings, fireside chats, panels, and networking. For more information about the Jones Las Vegas Technology and Innovation Conference, including a list of participating companies, visit their B2i Digital Featured Conference page. About RESTEM RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products, robust clinical development expertise, and cutting-edge-manufacturing capabilities, we advance two potentially groundbreaking programs, Restem-L, our umbilical cord lining stem cells (ULSCs) program for auto-immune diseases and our natural killer cell (NK) therapeutics targeting senescence and age-associated disorders. Our therapies are intended to treat a broad range of disabling diseases and are designed to improve patient outcomes, as well as overall health and wellness. RESTEM is headquartered in Miami, Florida. For more information, please visit and follow us on X and LinkedIn. Investor Contact LifeSci Advisors +1.617.430.7576 Media Contact Nelson Cabautan Restem Group, Inc. +1.800.490.0924
